Study Shows Castle Biosciences’ Gene Expression Profile Test Successfully Identified High Risk Disease In A Cohort Of 217 Melanoma Patients Who Underwent Sentinel Lymph Node Biopsy
CHICAGO--(BUSINESS WIRE)--Castle Biosciences Inc. today announced results of a 217-patient study demonstrating that its gene expression profile (GEP) test, DecisionDx-Melanoma, identified primary cutaneous (skin) melanoma tumors that were sentinel lymph node biopsy negative but were at high risk of metastasis. The GEP test also identified tumors that were unlikely to become metastatic, independent of nodal status. The data are being reviewed today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in the Melanoma/Skin Cancers Poster Highlights Session by David H. Lawson, M.D., Professor of Hematology and Medical Oncology, Winship Cancer Institute, Emory University.
Help employers find you! Check out all the jobs and post your resume.